A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)
A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)
NCT ID: NCT04887519 Phase: Status: COMPLETED Enrollment: 39 Completion: 2023-03-31
Conditions
Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase
Interventions
No Intervention
Summary
The aims of the study are to assess the safety profile of brigatinib and the clinical response rates in adults with Anaplastic Lymphoma Kinase (ALK)-Positive Metastatic Non Small Cell Lung Cancer (NSCLC). Treatment with brigatinib and follow-up will be according to routine clinical practice.
Study doctors will review the participants' medical records at the start of the study, then at 12 and 24 weeks after treatment starts.
Primary Outcome
Number of Participants Reporting One or More Adverse Events (AEs) of Special Interest